Tin tức & Cập nhật

Chỉ hiển thị Multimedia
Bimekizumab triumphs in bDMARD-naïve psoriatic arthritis patients

Bimekizumab triumphs in bDMARD-naïve psoriatic arthritis patients

20 Jun 2022 bởiRoshini Claire Anthony

Patients with psoriatic arthritis (PsA) with no prior exposure to biological disease-modifying antirheumatic drugs (bDMARDs) experience improvements in their condition when treated with bimekizumab, according to results of the phase III BE OPTIMAL trial.

20 Jun 2022